RTS, S/AS01 sebagai Vaksin Malaria Generasi Pertama

Komang Dendi Juliawan

  • Komang Dendi Juliawan Universitas Lampung
Keywords: Malaria, RTS,S/AS01 vaccine, circumsporozoite protein

Abstract

Malaria is an infectius disease caused by Plasmodium sp. The treatment for malaria with Artemisinin-based Combination Therapy (ACT) can cause resistance so a new effort is needed to reduce the morbidity of malaria. A better prevention method for preventing malaria is to use vaccines. The RTS,S/AS01 vaccine is the first generation malaria vaccine that has been applied in Ghana, Kenya and Malawi since early 2018. The vaccine consists of circumsporozoite protein antigen and hepatitis B. This vaccine has been shown to provide partial protection to children and has reach efficacy by 80%.

Downloads

Download data is not yet available.

Author Biography

Komang Dendi Juliawan, Universitas Lampung

Pendidikan Dokter Fakultas Kedokteran

References

Coppi A, Natarajan R, Pradel G, Bennett BL, James AR, Roggero MA, et al. 2011. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to a mammalian host. Journal of experimental medicine [Internet]. [disitasi Tanggal 14 December 2019]. Tersedia dari: http://jem.rupress.org.

Departemen Kesehatan Republik Indonesia. 2008. Pedoman penatalaksanaan kasus malaria di Indonesia. Jakarta: Departemen Kesehatan Republik Indonesia.

Dinas Kesehatan Pemerintah Provinsi Lampung. 2015. Profil kesehatan Provinsi Lampung tahun 2015. Bandar Lampung: Dinas Kesehatan Pemerintah Provinsi Lampung.

Gandhi K, Thera MA, Coulibaly D, Traore K, Guindo AB, Ouattara A, et al. 2014. Variation in the circumsporozoite protein of plasmodium falciparum: vaccine development implications. PLOS ONE. 9(7):1-9

Harijanto PN. Malaria. Dalam: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. 2014. Buku ajar ilmu penyakit Dalam. Edisi ke-6. Jakarta: Interna Publishing.

Malaria Vaccine Initiative. 2017. First-generation vaccine [internet]. PATH-MVI. [Diakses tanggal 14 Desember 2019]. Tersedia dari: http://www.malariavaccine.org.

Malaria Vaccine Initiative. 2017. Our research and development strategy [internet]. PATH-MVI. [Diakses tanggal 14 Desember 2019]. Tersedia dari: http://www.malariavaccine.org.

Malaria Vaccine Initiative. 2016. Fact sheet: RTS, S malaria vaccine candidate (MosquirixTM) [internet].PATH-MVI.[Diakses tanggal 14 Desember 2019].Tersedia dari: http://www.malariavaccine.org.

Malaria Vaccine Initiative. 2018. RTS,S frequently asked questions (FAQs) [internet]. PATH-VMI. [Diakses Tanggal 14 December 2019]. Tersedia dari: https://www.malariavaccine.org.

Plessmeyer ML, Reiter K, Shimp LR, Kotova S, Smith PD, Hurt DE, et al. 2009. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. JBC Papers in Press. 284(39):26951–26963.

Tucker K, Noe AR, Kotraiah V, Phares TW, Tsuji M, Nardin EH, et al. 2016. pre-erythrocytic vaccine candidates in malaria. InTech. 335-364.

Vaccine Investigation and Online Information Network (VIOLA). 2017. Protective antigens: CS from p. falciparum [internet]. VIOLA; [Diakses Tanggal 14 December 2019]. Tersedia dari: http://www.violinet.org.

World Health Organization. 2015. Guidelines for the treatment of malaria. 3rd Edition. Italy: WHO Library Cataloguing Data.

World Health Organization. 2018. World malaria report 2018. Switzerland: WHO Library Cataloguing Data.

Published
2019-12-30
How to Cite
Juliawan, K. (2019). RTS, S/AS01 sebagai Vaksin Malaria Generasi Pertama. Jurnal Ilmiah Kesehatan Sandi Husada, 10(2), 275-280. https://doi.org/10.35816/jiskh.v10i2.170

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.